Please login to the form below

Not currently logged in
Email:
Password:

AZ agrees generics deal with Torrent

AstraZeneca is to enter into an agreement with Torrent Pharmaceuticals to purchase the licenses to a portfolio of generic medicines

AstraZeneca (AZ) has announced it is to enter into an agreement with Indian based drug makers Torrent Pharmaceuticals to purchase the licenses to a portfolio of generic medicines.

The deal will see the anglo-Swedish pharmaceutical giants obtain from Torrent the licenses and market authorisations for 18 products in nine countries, with AZ looking to 'capitalise' on the increasing prospects for pharmaceutical companies in emerging markets, including India.

In a statement, AZ claimed that emerging markets are "forecast to contribute around 70 per cent of pharmaceutical industry growth in the next five years, and branded generics represent approximately 50 per cent by value in these emerging markets."

As part of the deal, for which no financial details were disclosed, AZ will also gain the flexibility to add further products and new countries for which the company sees expansion opportunities.

Torrent, who currently produce and supply its products into more than 50 countries, will continue to manufacture the medicines.

Tony Zook, head of AstraZeneca's global commercial organisation, said: "In markets where consumers and physicians have a strong preference for trusted brands, we believe AstraZeneca's long-standing reputation for quality is a sustainable competitive advantage. Working in partnership with Torrent will extend the range of branded medicines we can offer to patients in emerging markets, where we see continuing opportunities for our business to grow."

11th March 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics